CY1120303T1 - Βελτιωμενοι tnf συνδετες - Google Patents
Βελτιωμενοι tnf συνδετεςInfo
- Publication number
- CY1120303T1 CY1120303T1 CY20171101330T CY171101330T CY1120303T1 CY 1120303 T1 CY1120303 T1 CY 1120303T1 CY 20171101330 T CY20171101330 T CY 20171101330T CY 171101330 T CY171101330 T CY 171101330T CY 1120303 T1 CY1120303 T1 CY 1120303T1
- Authority
- CY
- Cyprus
- Prior art keywords
- tnf
- isvds
- connectors
- bind
- compounds
- Prior art date
Links
- 108060008682 Tumor Necrosis Factor Proteins 0.000 abstract 3
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 abstract 3
- 102100040247 Tumor necrosis factor Human genes 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 abstract 1
- 108060003951 Immunoglobulin Proteins 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 150000005829 chemical entities Chemical class 0.000 abstract 1
- 102000018358 immunoglobulin Human genes 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Treatment Of Liquids With Adsorbents In General (AREA)
- Organic Insulating Materials (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
Abstract
Η παρούσα εφεύρεση σχετίζεται με αλληλουχίες αμινοξέων, ενώσεις, και πεπτίδια που δεσμεύονται στον παράγοντα νέκρωσης όγκων α («TNF» ή «TNF-α»). Ειδικότερα, η παρούσα εφεύρεση σχετίζεται με βελτιωμένες μονές μεταβλητές επικράτειες ανοσοσφαιρίνης βαριάς αλυσίδας (επίσης αναφερόμενες στο κείμενο ως «ISV's» ή «ISVDs») που δεσμεύονται σε παράγοντα νέκρωσης όγκων α, καθώς και με πρωτεΐνες, πολυπεπτίδια και άλλα δομήματα, ενώσεις, μόρια ή χημικές οντότητες που περιλαμβάνουν τέτοιες ISVDs, όλα μαζί χαρακτηριζόμενα ως TNF συνδέτες. Άλλες πτυχές, υλοποιήσεις, χαρακτηριστικά, χρήσεις και πλεονεκτήματα της εφεύρεσης θα καταστούν προφανή στον ειδικευμένο με βάση την αποκάλυψη στο κείμενο.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562254375P | 2015-11-12 | 2015-11-12 | |
PCT/EP2016/077595 WO2017081320A1 (en) | 2015-11-12 | 2016-11-14 | Improved tnf binders |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1120303T1 true CY1120303T1 (el) | 2019-07-10 |
Family
ID=57348648
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20171101330T CY1120303T1 (el) | 2015-11-12 | 2017-12-19 | Βελτιωμενοι tnf συνδετες |
Country Status (36)
Country | Link |
---|---|
US (2) | US10544211B2 (el) |
EP (2) | EP3266798A3 (el) |
JP (2) | JP6962915B2 (el) |
KR (2) | KR20240029115A (el) |
CN (1) | CN108473563B (el) |
AU (2) | AU2016352943B2 (el) |
BR (1) | BR112018009714A8 (el) |
CA (2) | CA3005085A1 (el) |
CL (1) | CL2018001291A1 (el) |
CO (1) | CO2018005915A2 (el) |
CR (1) | CR20180311A (el) |
CY (1) | CY1120303T1 (el) |
DK (1) | DK3191511T3 (el) |
DO (1) | DOP2018000122A (el) |
EC (1) | ECSP18042569A (el) |
ES (1) | ES2662418T3 (el) |
GT (1) | GT201800095A (el) |
HK (1) | HK1248716A1 (el) |
HR (1) | HRP20171949T1 (el) |
HU (1) | HUE035805T2 (el) |
IL (2) | IL310373A (el) |
LT (1) | LT3191511T (el) |
MA (1) | MA41653A (el) |
MD (1) | MD3191511T2 (el) |
ME (1) | ME02954B (el) |
MX (1) | MX2018005992A (el) |
NO (1) | NO2768984T3 (el) |
PE (1) | PE20181317A1 (el) |
PH (1) | PH12018501025A1 (el) |
PL (1) | PL3191511T3 (el) |
PT (1) | PT3191511T (el) |
RS (1) | RS56676B1 (el) |
SG (1) | SG11201803975SA (el) |
SI (1) | SI3191511T1 (el) |
TN (1) | TN2018000159A1 (el) |
WO (1) | WO2017081320A1 (el) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11644471B2 (en) | 2010-09-30 | 2023-05-09 | Ablynx N.V. | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains |
CN108659121A (zh) | 2011-06-23 | 2018-10-16 | 埃博灵克斯股份有限公司 | 用于预测、检测和减少涉及免疫球蛋白单可变结构域的测定法中的非特异性蛋白干扰的技术 |
HUE050007T2 (hu) | 2014-05-16 | 2020-11-30 | Ablynx Nv | Immunglobulin variábilis domének |
NO2768984T3 (el) * | 2015-11-12 | 2018-06-09 | ||
GB201522394D0 (en) | 2015-12-18 | 2016-02-03 | Ucb Biopharma Sprl | Antibodies |
WO2021110817A1 (en) | 2019-12-06 | 2021-06-10 | Ablynx Nv | Polypeptides comprising immunoglobulin single variable domains targeting tnfa and ox40l |
IL293561A (en) | 2019-12-06 | 2022-08-01 | Ablynx Nv | Polypeptides comprising immunoglobulin with one variable domain targeting TNFa and IL-23 |
CN112300289B (zh) * | 2019-12-30 | 2022-06-10 | 中国药科大学 | RGD4C融合抗TNFα纳米抗体蛋白、制备方法及其应用 |
KR20230123497A (ko) * | 2020-12-18 | 2023-08-23 | 아블린쓰 엔.브이. | IL-6 및 TNF-α를 표적화하는 면역글로불린 단일 가변도메인을 포함하는 폴리펩티드 |
WO2024097571A1 (en) * | 2022-11-04 | 2024-05-10 | St. Jude Children's Research Hospital, Inc. | Nlrp12 and nlrc5 modulators and methods for using the same to modulate diseases |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK0656946T4 (da) | 1992-08-21 | 2010-07-26 | Univ Bruxelles | Immunoglobuliner uden lette kæder |
EP0739981A1 (en) | 1995-04-25 | 1996-10-30 | Vrije Universiteit Brussel | Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes |
WO1999023221A2 (en) | 1997-10-27 | 1999-05-14 | Unilever Plc | Multivalent antigen-binding proteins |
CA2321199A1 (en) | 1998-02-19 | 1999-08-26 | William A. Brady | Compositions and methods for regulating lymphocyte activation |
US20060002935A1 (en) | 2002-06-28 | 2006-01-05 | Domantis Limited | Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor |
US9321832B2 (en) | 2002-06-28 | 2016-04-26 | Domantis Limited | Ligand |
WO2004041865A2 (en) * | 2002-11-08 | 2004-05-21 | Ablynx N.V. | Stabilized single domain antibodies |
JP2006517789A (ja) | 2003-01-10 | 2006-08-03 | アブリンクス エン.ヴェー. | 治療用ポリペプチド、その相同物、その断片、および血小板媒介凝集の調節での使用 |
CA2529819A1 (en) | 2003-06-30 | 2004-09-23 | Domantis Limited | Pegylated single domain antibodies |
ATE485307T1 (de) | 2003-11-07 | 2010-11-15 | Ablynx Nv | Camelidae schwere ketten antikörper vhhs gegen epidermalen wachstumfaktor rezeptor (egfr) und ihre verwendung |
KR20070084170A (ko) | 2004-10-13 | 2007-08-24 | 아블린쓰 엔.브이. | 알쯔하이머병 등의 퇴행성 신경 질환의 치료 및 진단을위한 단일 도메인 카멜리드 항-아밀로이드 베타 항체 및이를 포함하는 폴리펩타이드 |
AU2005311101B8 (en) | 2004-12-02 | 2011-03-03 | Domantis Limited | Anti-IL-IRI single domain antibodies and therapeutic uses |
CN103254309B (zh) * | 2005-05-18 | 2017-09-26 | 埃博灵克斯股份有限公司 | 针对肿瘤坏死因子α的改进的纳米体TM |
CA2960105A1 (en) | 2005-05-20 | 2006-11-23 | Ablynx Nv | Single domain vhh antibodies against von willebrand factor |
DE102005023617A1 (de) * | 2005-05-21 | 2006-11-23 | Aspre Ag | Verfahren zum Mischen von Farben in einem Display |
AU2006286563B2 (en) | 2005-08-30 | 2012-02-23 | Intrexon Actobiotics Nv | Anti-TNF alpha producing lactic acid bacteria for the treatment of chronic enterocolitis |
AU2006321364B2 (en) | 2005-12-01 | 2011-11-10 | Domantis Limited | Noncompetitive domain antibody formats that bind Interleukin 1 Receptor type 1 |
EP1957537A2 (en) | 2005-12-01 | 2008-08-20 | Domantis Limited | Competitive domain antibody formats that bind interleukin 1 receptor type 1 |
FR2894741B1 (fr) | 2005-12-08 | 2009-12-04 | Centre Nat Etd Spatiales | Chaine de reception par satellite |
WO2007085814A1 (en) | 2006-01-24 | 2007-08-02 | Domantis Limited | Fusion proteins that contain natural junctions |
US8629244B2 (en) | 2006-08-18 | 2014-01-14 | Ablynx N.V. | Interleukin-6 receptor binding polypeptides |
CN101611056A (zh) | 2006-12-05 | 2009-12-23 | 埃博灵克斯股份有限公司 | 能够结合于血清蛋白的肽 |
CA2687903C (en) | 2007-05-24 | 2016-09-13 | Ablynx N.V. | Amino acid sequences directed against rank-l and polypeptides comprising the same for the treatment of bone diseases and disorders |
CN101970490A (zh) | 2007-11-27 | 2011-02-09 | 埃博灵克斯股份有限公司 | 针对异二聚体细胞因子和/或其受体的氨基酸序列以及包括所述氨基酸序列的多肽 |
DE102008023620A1 (de) | 2008-05-15 | 2009-11-19 | Mettler-Toledo (Albstadt) Gmbh | Funktionseinheit mit einer aufrufbaren Funktion und Verfahren zu deren Aufruf |
RU2010151725A (ru) | 2008-05-16 | 2012-06-27 | Аблинкс Нв (Be) | Аминокислотные последовательности, направленные против cхcr4 и других gpcr, и соединения, включаюшие их |
JP2012517818A (ja) * | 2009-02-19 | 2012-08-09 | グラクソ グループ リミテッド | 改善された抗tnfr1ポリペプチド、抗体可変ドメインおよびアンタゴニスト |
JP5647222B2 (ja) | 2009-04-10 | 2014-12-24 | アブリンクス エン.ヴェー. | Il−6r関連疾患及び障害の治療のためのil−6rに指向性を有する改善されたアミノ酸配列及びこれを含むポリペプチド |
WO2010130832A2 (en) | 2009-05-15 | 2010-11-18 | Ablynx N.V. | Amino acid sequences directed against dickkopf-1 and polypeptides comprising the same for the treatment of diseases and disorders associated with bone loss and/or osteolytic lesions |
EA201270174A1 (ru) | 2009-07-16 | 2012-07-30 | Глэксо Груп Лимитед | Отдельные связывающиеся вариабельные домены с улучшенными свойствами, направленные против сывороточного альбумина |
US9120855B2 (en) | 2010-02-10 | 2015-09-01 | Novartis Ag | Biologic compounds directed against death receptor 5 |
CN103917560B (zh) | 2011-03-28 | 2017-05-24 | 埃博灵克斯股份有限公司 | 双特异性抗‑cxcr7免疫球蛋白单可变结构域 |
AU2012271974B2 (en) | 2011-06-23 | 2017-01-12 | Ablynx Nv | Serum albumin binding proteins |
CN108659121A (zh) * | 2011-06-23 | 2018-10-16 | 埃博灵克斯股份有限公司 | 用于预测、检测和减少涉及免疫球蛋白单可变结构域的测定法中的非特异性蛋白干扰的技术 |
EA027160B1 (ru) * | 2011-08-17 | 2017-06-30 | Глаксо Груп Лимитед | Модифицированные белки и пептиды |
WO2014111550A1 (en) | 2013-01-17 | 2014-07-24 | Glaxosmithkline Intellectual Property Development Limited | Modified anti-serum albumin binding proteins |
HUE050007T2 (hu) * | 2014-05-16 | 2020-11-30 | Ablynx Nv | Immunglobulin variábilis domének |
NO2768984T3 (el) * | 2015-11-12 | 2018-06-09 |
-
2012
- 2012-10-19 NO NO12841612A patent/NO2768984T3/no unknown
-
2016
- 2016-11-13 MA MA041653A patent/MA41653A/fr unknown
- 2016-11-14 TN TNP/2018/000159A patent/TN2018000159A1/en unknown
- 2016-11-14 AU AU2016352943A patent/AU2016352943B2/en active Active
- 2016-11-14 EP EP17184686.8A patent/EP3266798A3/en active Pending
- 2016-11-14 MD MDE20170066T patent/MD3191511T2/ro unknown
- 2016-11-14 EP EP16798122.4A patent/EP3191511B1/en active Active
- 2016-11-14 BR BR112018009714A patent/BR112018009714A8/pt active Search and Examination
- 2016-11-14 CA CA3005085A patent/CA3005085A1/en active Pending
- 2016-11-14 MX MX2018005992A patent/MX2018005992A/es unknown
- 2016-11-14 CA CA3234178A patent/CA3234178A1/en active Pending
- 2016-11-14 RS RS20171299A patent/RS56676B1/sr unknown
- 2016-11-14 SI SI201630013T patent/SI3191511T1/en unknown
- 2016-11-14 LT LTEP16798122.4T patent/LT3191511T/lt unknown
- 2016-11-14 ME MEP-2017-291A patent/ME02954B/me unknown
- 2016-11-14 IL IL310373A patent/IL310373A/en unknown
- 2016-11-14 US US15/501,011 patent/US10544211B2/en active Active
- 2016-11-14 PT PT167981224T patent/PT3191511T/pt unknown
- 2016-11-14 PL PL16798122T patent/PL3191511T3/pl unknown
- 2016-11-14 KR KR1020247005963A patent/KR20240029115A/ko active Application Filing
- 2016-11-14 HU HUE16798122A patent/HUE035805T2/en unknown
- 2016-11-14 IL IL259269A patent/IL259269B1/en unknown
- 2016-11-14 SG SG11201803975SA patent/SG11201803975SA/en unknown
- 2016-11-14 ES ES16798122.4T patent/ES2662418T3/es active Active
- 2016-11-14 CN CN201680076588.6A patent/CN108473563B/zh active Active
- 2016-11-14 JP JP2018524836A patent/JP6962915B2/ja active Active
- 2016-11-14 PE PE2018000766A patent/PE20181317A1/es unknown
- 2016-11-14 CR CR20180311A patent/CR20180311A/es unknown
- 2016-11-14 KR KR1020187016731A patent/KR102641194B1/ko active IP Right Grant
- 2016-11-14 DK DK16798122.4T patent/DK3191511T3/en active
- 2016-11-14 WO PCT/EP2016/077595 patent/WO2017081320A1/en active Application Filing
-
2017
- 2017-03-13 US US15/456,824 patent/US9745372B2/en active Active
- 2017-12-01 HK HK18108106.4A patent/HK1248716A1/zh unknown
- 2017-12-15 HR HRP20171949TT patent/HRP20171949T1/hr unknown
- 2017-12-19 CY CY20171101330T patent/CY1120303T1/el unknown
-
2018
- 2018-05-11 CL CL2018001291A patent/CL2018001291A1/es unknown
- 2018-05-11 GT GT201800095A patent/GT201800095A/es unknown
- 2018-05-11 DO DO2018000122A patent/DOP2018000122A/es unknown
- 2018-05-15 PH PH12018501025A patent/PH12018501025A1/en unknown
- 2018-06-05 EC ECIEPI201842569A patent/ECSP18042569A/es unknown
- 2018-06-08 CO CONC2018/0005915A patent/CO2018005915A2/es unknown
-
2021
- 2021-10-14 JP JP2021168871A patent/JP7357038B2/ja active Active
-
2023
- 2023-01-10 AU AU2023200113A patent/AU2023200113A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1120303T1 (el) | Βελτιωμενοι tnf συνδετες | |
MX2023007520A (es) | Aglutinantes de albumina de suero mejorados. | |
EA201792572A1 (ru) | Антитела к ox40 и их применение | |
MX2023005374A (es) | Aglutinantes de albumina serica mejorados. | |
MX2019008536A (es) | Aglutinantes de albumina serica mejorados. | |
CY1122389T1 (el) | Αντισωματα εναντι διεγειρομενου με γλυκοκορτικοειδες υποδοχεα παραγοντα νεκρωσης ογκου (gitr) και χρησεις αυτων | |
MX2018006072A (es) | Anticuerpos contra receptor de factor de necrosis de tumor inducido por glucocorticoides (gitr) y usos de los mismos. | |
EA201892691A1 (ru) | Однодоменный белок, связывающий сывороточный альбумин | |
EA201592006A1 (ru) | Новые биспецифические связывающие молекулы с противоопухолевой активностью | |
EA201791057A1 (ru) | Антигенсвязывающие молекулы, содержащие тримерный лиганд семейства tnf | |
EA201400568A1 (ru) | Альбуминсвязывающие антитела и их связывающие фрагменты | |
EA202092417A1 (ru) | Химерные рецепторы к dll3 и способы их применения | |
MX2018004545A (es) | Anticuerpos anti-age y metodos para utilizarlos. | |
RU2021124437A (ru) | Конструкции, направленные на комплексы пептида afp/mhc, и виды их использования | |
EA201591478A1 (ru) | Биспецифические антитела против фно и ил-17 | |
EA201890320A1 (ru) | Молекулы антител, которые связывают cd79 | |
EA201691589A1 (ru) | Стабилизированные основанные на фибронектине каркасные молекулы | |
EA202092769A1 (ru) | Антитела против cd63, их конъюгаты и применения | |
EA202090533A2 (ru) | Антитела к ox40 и их применение | |
CY1115985T1 (el) | Μεθοδος για παραγωγη μοριων δεσμευσης για τον ανθρωπινο οχ40 υποδοχεα |